Detalhe da pesquisa
1.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635381
2.
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Blood
; 140(20): 2170-2174, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797468
3.
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
J Clin Psychopharmacol
; 32(1): 36-45, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22198451
4.
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
J Clin Med
; 11(1)2021 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35011768
5.
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Leukemia
; 36(5): 1432-1435, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220402
6.
Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia.
Neuropsychiatr Dis Treat
; 8: 247-57, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22745558